REFERENCES
1. Pepine CJ, Ferdinand KC, Shaw LJ, et al; ACC CVD in Women Committee. Emergence of nonobstructive coronary artery disease: a woman’s problem and need for change in definition on angiography. J Am Coll Cardiol. 2015;66:1918-33.
2. Likoff W, Segal BL, Kasparian H. Paradox of normal selective coronary arteriograms in patients considered to have unmistakable coronary heart disease. N Engl J Med. 1967;276:1063-6.
3. Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation. 2004;109:568-72.
4. Cannon RO 3rd, Epstein SE. “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988;61:1338-43.
5. Masi S, Rizzoni D, Taddei S, et al. Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. Eur Heart J. 2021;42:2590-604.
6. Kelshiker MA, Seligman H, Howard JP, et al; Coronary Flow Outcomes Reviewing Committee. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J. 2022;43:1582-93.
7. Gdowski MA, Murthy VL, Doering M, Monroy-Gonzalez AG, Slart R, Brown DL. Association of isolated coronary microvascular dysfunction with mortality and major adverse cardiac events: a systematic review and meta-analysis of aggregate data. J Am Heart Assoc. 2020;9:e014954.
8. Rehan R, Yong A, Ng M, Weaver J, Puranik R. Coronary microvascular dysfunction: a review of recent progress and clinical implications. Front Cardiovasc Med. 2023;10:1111721.
9. Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:2625-41.
10. Crea F, Montone RA, Rinaldi R. Pathophysiology of coronary microvascular dysfunction. Circ J. 2022;86:1319-28.
11. Qian G, Zhang Y, Dong W, et al. Effects of nicorandil administration on infarct size in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the CHANGE trial. J Am Heart Assoc. 2022;11:e026232.
12. Zhang Y, Zhao J, Ding R, Niu W, He Z, Liang C. Pre-treatment with compound Danshen dripping pills prevents lipid infusion-induced microvascular dysfunction in mice. Pharm Biol. 2020;58:701-6.
13. Kenkre TS, Malhotra P, Johnson BD, et al. Ten-year mortality in the WISE study (Women’s ischemia syndrome evaluation). Circ Cardiovasc Qual Outcomes. 2017;10:e003863.
14. Fatade YA, Dave EK, Vatsa N, et al. Obesity and diabetes in heart disease in women. Metab Target Organ Damage. 2024;4:22.
15. Shimokawa H, Suda A, Takahashi J, et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart J. 2021;42:4592-600.
16. Mileva N, Nagumo S, Mizukami T, et al. Prevalence of coronary microvascular disease and coronary vasospasm in patients with nonobstructive coronary artery disease: systematic review and meta-analysis. J Am Heart Assoc. 2022;11:e023207.
17. van Kranenburg M, Magro M, Thiele H, et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging. 2014;7:930-9.
18. Konijnenberg LSF, Damman P, Duncker DJ, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc Res. 2020;116:787-805.
19. Cenko E, van der Schaar M, Yoon J, et al. Sex-specific treatment effects after primary percutaneous intervention: a study on coronary blood flow and delay to hospital presentation. J Am Heart Assoc. 2019;8:e011190.
20. He Z, Li N, Zhang W, et al. Efficacy and safety of Shexiang Baoxin Pill in patients with angina and non-obstructive coronary arteries: a multicenter, randomized, double-blind, placebo-controlled, phase IV clinical trial. Phytomedicine. 2025;139:156556.
21. O’Kelly AC, Michos ED, Shufelt CL, et al. Pregnancy and reproductive risk factors for cardiovascular disease in women. Circ Res. 2022;130:652-72.
22. Allal-Elasmi M, Haj Taieb S, Hsairi M, et al. The metabolic syndrome: prevalence, main characteristics and association with socio-economic status in adults living in Great Tunis. Diabetes Metab. 2010;36:204-8.
23. Corcoran D, Young R, Adlam D, et al. Coronary microvascular dysfunction in patients with stable coronary artery disease: the CE-MARC 2 coronary physiology sub-study. Int J Cardiol. 2018;266:7-14.
24. Seo KW, Lim HS, Yoon MH, et al. The impact of microvascular resistance on the discordance between anatomical and functional evaluations of intermediate coronary disease. EuroIntervention. 2017;13:e185-92.
25. Rahman H, Ryan M, Lumley M, et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation. 2019;140:1805-16.
26. Barton D, Xie F, O’Leary E, Chatzizisis YS, Pavlides G, Porter TR. The relationship of capillary blood flow assessments with real time myocardial perfusion echocardiography to invasively derived microvascular and epicardial assessments. J Am Soc Echocardiogr. 2019;32:1095-101.
27. AlBadri A, Eshtehardi P, Hung OY, et al. Coronary microvascular dysfunction is associated with significant plaque burden and diffuse epicardial atherosclerotic disease. JACC Cardiovasc Interv. 2019;12:1519-20.
28. Nishi T, Murai T, Ciccarelli G, et al. Prognostic value of coronary microvascular function measured immediately after percutaneous coronary intervention in stable coronary artery disease: an international multicenter study. Circ Cardiovasc Interv. 2019;12:e007889.
29. Ekenbäck C, Jokhaji F, Östlund-Papadogeorgos N, et al. Changes in index of microcirculatory resistance during PCI in the left anterior descending coronary artery in relation to total length of implanted stents. J Interv Cardiol. 2019;2019:1397895.
30. Gupta A, Taqueti VR, van de Hoef TP, et al. Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation. 2017;136:2325-36.
31. Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131:19-27.
32. Canu M, Khouri C, Marliere S, et al. Prognostic significance of severe coronary microvascular dysfunction post-PCI in patients with STEMI: a systematic review and meta-analysis. PLoS One. 2022;17:e0268330.
33. Seraphim A, Dowsing B, Rathod KS, et al. Quantitative myocardial perfusion predicts outcomes in patients with prior surgical revascularization. J Am Coll Cardiol. 2022;79:1141-51.
34. Robbers LF, Eerenberg ES, Teunissen PF, et al. Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage. Eur Heart J. 2013;34:2346-53.
35. Heusch G, Andreadou I, Bell R, et al. Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection. Redox Biol. 2023;67:102894.
36. Carrick D, Haig C, Ahmed N, et al. Temporal evolution of myocardial hemorrhage and edema in patients after acute ST-segment elevation myocardial infarction: pathophysiological insights and clinical implications. J Am Heart Assoc. 2016;5:e002834.
37. Skyschally A, Walter B, Heusch G. Coronary microembolization during early reperfusion: infarct extension, but protection by ischaemic postconditioning. Eur Heart J. 2013;34:3314-21.
38. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2016;37:1024-33.
39. Niccoli G, Montone RA, Ibanez B, et al. Optimized treatment of ST-elevation myocardial infarction. Circ Res. 2019;125:245-58.
40. Chang X, Lochner A, Wang HH, et al. Coronary microvascular injury in myocardial infarction: perception and knowledge for mitochondrial quality control. Theranostics. 2021;11:6766-85.
41. Bertani F, Di Francesco D, Corrado MD, Talmon M, Fresu LG, Boccafoschi F. Paracrine shear-stress-dependent signaling from endothelial cells affects downstream endothelial function and inflammation. Int J Mol Sci. 2021;22:13300.
42. Zhang Y, Zhao J, Ren C, et al. Free fatty acids induce coronary microvascular dysfunction via inhibition of the AMPK/KLF2/eNOS signaling pathway. Int J Mol Med. 2023;51:34.
43. Ford TJ, Corcoran D, Padmanabhan S, et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. Eur Heart J. 2020;41:3239-52.
44. Zhang Z, Li X, He J, et al. Molecular mechanisms of endothelial dysfunction in coronary microcirculation dysfunction. J Thromb Thrombolysis. 2023;56:388-97.
45. Theuerle J, Farouque O, Vasanthakumar S, et al. Plasma endothelin-1 and adrenomedullin are associated with coronary artery function and cardiovascular outcomes in humans. Int J Cardiol. 2019;291:168-72.
46. Kassi E, Spilioti E, Nasiri-Ansari N, et al. Vascular inflammation and atherosclerosis: the role of estrogen receptors. Curr Med Chem. 2015;22:2651-65.
47. Steinberg RR, Dragan A, Mehta PK, Toleva O. Coronary microvascular disease in women: epidemiology, mechanisms, evaluation, and treatment. Can J Physiol Pharmacol. 2024;102:594-606.
48. Bassuk SS, Manson JE. The timing hypothesis: do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism. 2016;65:794-803.
49. Witkowski S, Serviente C. Endothelial dysfunction and menopause: is exercise an effective countermeasure? Climacteric. 2018;21:267-75.
50. Zhou M, Yu Y, Chen R, et al. Wall shear stress and its role in atherosclerosis. Front Cardiovasc Med. 2023;10:1083547.
51. Yang F, Zhang Y, Zhu J, et al. Laminar flow protects vascular endothelial tight junctions and barrier function via maintaining the expression of long non-coding RNA MALAT1. Front Bioeng Biotechnol. 2020;8:647.
52. Samady H, Eshtehardi P, McDaniel MC, et al. Coronary artery wall shear stress is associated with progression and transformation of atherosclerotic plaque and arterial remodeling in patients with coronary artery disease. Circulation. 2011;124:779-88.
53. Bajraktari A, Bytyçi I, Henein MY. High coronary wall shear stress worsens plaque vulnerability: a systematic review and meta-analysis. Angiology. 2021;72:706-14.
54. Siasos G, Tsigkou V, Zaromytidou M, et al. Role of local coronary blood flow patterns and shear stress on the development of microvascular and epicardial endothelial dysfunction and coronary plaque. Curr Opin Cardiol. 2018;33:638-44.
55. Wong CCY, Javadzadegan A, Ada C, et al. Fractional flow reserve and instantaneous wave-free ratio predict pathological wall shear stress in coronary arteries: implications for understanding the pathophysiological impact of functionally significant coronary stenoses. J Am Heart Assoc. 2022;11:e023502.
56. Mailey JA, Moore JS, Brennan PF, et al. Assessment of hemodynamic indices of conjunctival microvascular function in patients with coronary microvascular dysfunction. Microvasc Res. 2023;147:104480.
57. Hiteshi AK, Li D, Gao Y, et al. Gender differences in coronary artery diameter are not related to body habitus or left ventricular mass. Clin Cardiol. 2014;37:605-9.
58. Gould KL, Johnson NP, Bateman TM, et al. Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J Am Coll Cardiol. 2013;62:1639-53.
59. Patel MB, Bui LP, Kirkeeide RL, Gould KL. Imaging microvascular dysfunction and mechanisms for female-male differences in CAD. JACC Cardiovasc Imaging. 2016;9:465-82.
60. Xu Y, Kovacic JC. Endothelial to mesenchymal transition in health and disease. Annu Rev Physiol. 2023;85:245-67.
61. Evrard SM, Lecce L, Michelis KC, et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun. 2016;7:11853.
62. Lecce L, Xu Y, V’Gangula B, et al. Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype. J Clin Invest. 2021;131:e131178.
63. Reventun P, Sánchez-Esteban S, Cook-Calvete A, et al. Endothelial ILK induces cardioprotection by preventing coronary microvascular dysfunction and endothelial-to-mesenchymal transition. Basic Res Cardiol. 2023;118:28.
64. Cho DI, Ahn JH, Kang BG, et al. ANGPTL4 prevents atherosclerosis by preserving KLF2 to suppress EndMT and mitigates endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2025;45:1742-61.
65. Li H, Jia Y, Chen Z, et al. Bioinformatics analysis of coronary microvascular dysfunction in rats based on single-cell RNA sequencing. Sci Rep. 2025;15:5050.
66. Sabe SA, Feng J, Sellke FW, Abid MR. Mechanisms and clinical implications of endothelium-dependent vasomotor dysfunction in coronary microvasculature. Am J Physiol Heart Circ Physiol. 2022;322:H819-41.
67. Jia G, Aroor AR, Jia C, Sowers JR. Endothelial cell senescence in aging-related vascular dysfunction. Biochim Biophys Acta Mol Basis Dis. 2019;1865:1802-9.
68. Clayton ZS, Hutton DA, Brunt VE, et al. Apigenin restores endothelial function by ameliorating oxidative stress, reverses aortic stiffening, and mitigates vascular inflammation with aging. Am J Physiol Heart Circ Physiol. 2021;321:H185-96.
69. Lee MY, Wang Y, Vanhoutte PM. Senescence of cultured porcine coronary arterial endothelial cells is associated with accelerated oxidative stress and activation of NFkB. J Vasc Res. 2010;47:287-98.
70. Man AWC, Li H, Xia N. The role of sirtuin1 in regulating endothelial function, arterial remodeling and vascular aging. Front Physiol. 2019;10:1173.
71. Donato AJ, Magerko KA, Lawson BR, Durrant JR, Lesniewski LA, Seals DR. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol. 2011;589:4545-54.
72. Zarzuelo MJ, López-Sepúlveda R, Sánchez M, et al. SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging. Biochem Pharmacol. 2013;85:1288-96.
73. Bochaton T, Lassus J, Paccalet A, et al. Association of myocardial hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in STEMI patients. PLoS One. 2021;16:e0245684.
74. Long M, Huang Z, Zhuang X, et al. Association of inflammation and endothelial dysfunction with coronary microvascular resistance in patients with cardiac syndrome X. Arq Bras Cardiol. 2017;109:397-403.
75. Cosín-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol. 2003;41:1468-74.
76. Suzuki M, Shimizu H, Miyoshi A, Takagi Y, Sato S, Nakamura Y. Association of coronary inflammation and angiotensin II with impaired microvascular reperfusion in patients with ST-segment elevation myocardial infarction. Int J Cardiol. 2011;146:254-6.
77. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
78. Dai L, Zhu L, Ma S, et al. Berberine alleviates NLRP3 inflammasome induced endothelial junction dysfunction through Ca2+ signalling in inflammatory vascular injury. Phytomedicine. 2022;101:154131.
79. Theofilis P, Sagris M, Oikonomou E, et al. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines. 2021;9:781.
80. Karamitsos K, Oikonomou E, Theofilis P, et al. The role of NLRP3 inflammasome in type 2 diabetes mellitus and its macrovascular complications. J Clin Med. 2025;14:4606.
81. Zhang Y, Song Z, Huang S, et al. Aloe emodin relieves Ang II-induced endothelial junction dysfunction via promoting ubiquitination mediated NLRP3 inflammasome inactivation. J Leukoc Biol. 2020;108:1735-46.
82. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339:161-6.
83. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121:2437-45.
84. Houssari M, Dumesnil A, Tardif V, et al. Lymphatic and immune cell cross-talk regulates cardiac recovery after experimental myocardial infarction. Arterioscler Thromb Vasc Biol. 2020;40:1722-37.
85. Laroumanie F, Douin-Echinard V, Pozzo J, et al. CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014;129:2111-24.
86. Bansal SS, Ismahil MA, Goel M, et al. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail. 2017;10:e003688.
87. Trincot CE, Xu W, Zhang H, et al. Adrenomedullin induces cardiac lymphangiogenesis after myocardial infarction and regulates cardiac edema via connexin 43. Circ Res. 2019;124:101-13.
88. Giannoni E, Guignard L, Knaup Reymond M, et al. Estradiol and progesterone strongly inhibit the innate immune response of mononuclear cells in newborns. Infect Immun. 2011;79:2690-8.
89. d’Adesky ND, de Rivero Vaccari JP, Bhattacharya P, et al. Nicotine alters estrogen receptor-beta-regulated inflammasome activity and exacerbates ischemic brain damage in female rats. Int J Mol Sci. 2018;19:1330.
90. Moran CA, Collins LF, Beydoun N, et al. Cardiovascular implications of immune disorders in women. Circ Res. 2022;130:593-610.
91. McCarthy M, Raval AP. The peri-menopause in a woman’s life: a systemic inflammatory phase that enables later neurodegenerative disease. J Neuroinflammation. 2020;17:317.
92. Nabeebaccus AA, Reumiller CM, Shen J, Zoccarato A, Santos CXC, Shah AM. The regulation of cardiac intermediary metabolism by NADPH oxidases. Cardiovasc Res. 2023;118:3305-19.
93. Xie Y, Nishijima Y, Zinkevich NS, et al. NADPH oxidase 4 contributes to TRPV4-mediated endothelium-dependent vasodilation in human arterioles by regulating protein phosphorylation of TRPV4 channels. Basic Res Cardiol. 2022;117:24.
94. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319:E827-34.
95. Li Y, Pagano PJ. Microvascular NADPH oxidase in health and disease. Free Radic Biol Med. 2017;109:33-47.
96. Niccoli G, Celestini A, Calvieri C, et al. Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. Eur Heart J Acute Cardiovasc Care. 2013;2:379-88.
97. Lassègue B, Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol. 2010;30:653-61.
98. Loffredo L, Ivanov V, Ciobanu N, et al. Low-grade endotoxemia and NOX2 in patients with coronary microvascular angina. Kardiol Pol. 2022;80:911-8.
99. Ottolini M, Hong K, Cope EL, et al. Local peroxynitrite impairs endothelial transient receptor potential vanilloid 4 channels and elevates blood pressure in obesity. Circulation. 2020;141:1318-33.
100. Camici PG, Tschöpe C, Di Carli MF, Rimoldi O, Van Linthout S. Coronary microvascular dysfunction in hypertrophy and heart failure. Cardiovasc Res. 2020;116:806-16.
101. Giannopoulos AA, Buechel RR, Kaufmann PA. Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies. J Nucl Cardiol. 2023;30:800-10.
102. Ismail TF, Hsu LY, Greve AM, et al. Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study. J Cardiovasc Magn Reson. 2014;16:49.
103. Timmer SA, Knaapen P, Germans T, et al. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Am J Physiol Heart Circ Physiol. 2011;301:H129-37.
104. Soliman OI, Geleijnse ML, Michels M, et al. Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:1321-7.
105. Rouet-Benzineb P, Merval R, Polidano E. Effects of hypoestrogenism and/or hyperaldosteronism on myocardial remodeling in female mice. Physiol Rep. 2018;6:e13912.
106. Almeida SA, Claudio ER, Mengal V, et al. Exercise training reduces cardiac dysfunction and remodeling in ovariectomized rats submitted to myocardial infarction. PLoS One. 2014;9:e115970.
107. Yung LM, Wong WT, Tian XY, et al. Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLoS One. 2011;6:e17437.
108. Rigattieri S, Barbato E, Berry C. Microvascular resistance reserve: a reference test of the coronary microcirculation? Eur Heart J. 2023;44:2870-2.
109. Lee JM, Kim HK, Lim KS, et al. Influence of local myocardial damage on index of microcirculatory resistance and fractional flow reserve in target and nontarget vascular territories in a porcine microvascular injury model. JACC Cardiovasc Interv. 2018;11:717-24.
110. De Maria GL, Alkhalil M, Wolfrum M, et al. The ATI score (age-thrombus burden-index of microcirculatory resistance) determined during primary percutaneous coronary intervention predicts final infarct size in patients with ST-elevation myocardial infarction: a cardiac magnetic resonance validation study. EuroIntervention. 2017;13:935-43.
111. De Maria GL, Alkhalil M, Wolfrum M, et al. Index of microcirculatory resistance as a tool to characterize microvascular obstruction and to predict infarct size regression in patients with STEMI undergoing primary PCI. JACC Cardiovasc Imaging. 2019;12:837-48.
112. Fineschi M, Verna E, Mezzapelle G, et al. Assessing MICRO-vascular resistances via IMR to predict outcome in STEMI patients with multivessel disease undergoing primary PCI (AMICRO): rationale and design of a prospective multicenter clinical trial. Am Heart J. 2017;187:37-44.
113. Faustino M, Baptista SB, Freitas A, et al. The index of microcirculatory resistance as a predictor of echocardiographic left ventricular performance recovery in patients with ST-elevation acute myocardial infarction undergoing successful primary angioplasty. J Interv Cardiol. 2016;29:137-45.
114. Palmer S, Layland J, Carrick D, et al. The index of microcirculatory resistance postpercutaneous coronary intervention predicts left ventricular recovery in patients with thrombolyzed ST-segment elevation myocardial infarction. J Interv Cardiol. 2016;29:146-54.
115. Ahn JM, Zimmermann FM, Gullestad L, et al. Microcirculatory resistance predicts allograft rejection and cardiac events after heart transplantation. J Am Coll Cardiol. 2021;78:2425-35.
116. De Bruyne B, Pijls NHJ, Gallinoro E, et al. Microvascular resistance reserve for assessment of coronary microvascular function: JACC technology corner. J Am Coll Cardiol. 2021;78:1541-9.
117. Boerhout CKM, Lee JM, de Waard GA, et al. Microvascular resistance reserve: diagnostic and prognostic performance in the ILIAS registry. Eur Heart J. 2023;44:2862-9.
118. Sun D, Wang J, Toan S, et al. Molecular mechanisms of coronary microvascular endothelial dysfunction in diabetes mellitus: focus on mitochondrial quality surveillance. Angiogenesis. 2022;25:307-29.
119. Wang J, Toan S, Zhou H. New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury. Angiogenesis. 2020;23:299-314.
120. Viloria MAD, Li Q, Lu W, et al. Effect of exercise training on cardiac mitochondrial respiration, biogenesis, dynamics, and mitophagy in ischemic heart disease. Front Cardiovasc Med. 2022;9:949744.
121. Zhu H, Toan S, Mui D, Zhou H. Mitochondrial quality surveillance as a therapeutic target in myocardial infarction. Acta Physiol. 2021;231:e13590.
122. Zhou H, Ren J, Toan S, Mui D. Role of mitochondrial quality surveillance in myocardial infarction: from bench to bedside. Ageing Res Rev. 2021;66:101250.
123. Ollauri-Ibáñez C, Núñez-Gómez E, Egido-Turrión C, et al. Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis. Angiogenesis. 2020;23:231-47.
124. Xian H, Liou YC. Functions of outer mitochondrial membrane proteins: mediating the crosstalk between mitochondrial dynamics and mitophagy. Cell Death Differ. 2021;28:827-42.
125. Whitley BN, Engelhart EA, Hoppins S. Mitochondrial dynamics and their potential as a therapeutic target. Mitochondrion. 2019;49:269-83.
126. Zhou H, Hu S, Jin Q, et al. Mff-dependent mitochondrial fission contributes to the pathogenesis of cardiac microvasculature ischemia/reperfusion injury via induction of mROS-mediated cardiolipin oxidation and HK2/VDAC1 disassociation-involved mPTP opening. J Am Heart Assoc. 2017;6:e005328.
127. Liu N, Wu J, Zhang L, et al. Hydrogen sulphide modulating mitochondrial morphology to promote mitophagy in endothelial cells under high-glucose and high-palmitate. J Cell Mol Med. 2017;21:3190-203.
128. Chen C, Gao JL, Liu MY, et al. Mitochondrial fission inhibitors suppress endothelin-1-induced artery constriction. Cell Physiol Biochem. 2017;42:1802-11.
129. Shi Y, Fan S, Wang D, et al. FOXO1 inhibition potentiates endothelial angiogenic functions in diabetes via suppression of ROCK1/Drp1-mediated mitochondrial fission. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2481-94.
130. Kleinbongard P, Gedik N, Kirca M, et al. Mitochondrial and contractile function of human right atrial tissue in response to remote ischemic conditioning. J Am Heart Assoc. 2018;7:e009540.
131. Lugus JJ, Ngoh GA, Bachschmid MM, Walsh K. Mitofusins are required for angiogenic function and modulate different signaling pathways in cultured endothelial cells. J Mol Cell Cardiol. 2011;51:885-93.
132. Kim D, Sesaki H, Roy S. Reduced levels of Drp1 protect against development of retinal vascular lesions in diabetic retinopathy. Cells. 2021;10:1379.
133. Xing H, Zhang Z, Shi G, et al. Chronic inhibition of mROS protects against coronary endothelial dysfunction in mice with diabetes. Frontiers in cell and developmental biology. 2021;9:6438.
134. Nakai R, Varnum S, Field RL, et al. Mitochondria transfer-based therapies reduce the morbidity and mortality of Leigh syndrome. Nat Metab. 2024;6:1886-96.
135. Borcherding N, Brestoff JR. The power and potential of mitochondria transfer. Nature. 2023;623:283-91.
136. Lemasters JJ. Variants of mitochondrial autophagy: types 1 and 2 mitophagy and micromitophagy (Type 3). Redox Biol. 2014;2:749-54.
137. Hughes WE, Beyer AM, Gutterman DD. Vascular autophagy in health and disease. Basic Res Cardiol. 2020;115:41.
138. Zhou H, Zhu P, Wang J, Zhu H, Ren J, Chen Y. Pathogenesis of cardiac ischemia reperfusion injury is associated with CK2α-disturbed mitochondrial homeostasis via suppression of FUNDC1-related mitophagy. Cell Death Differ. 2018;25:1080-93.
139. Li C, Tan Y, Wu J, et al. Resveratrol improves Bnip3-related mitophagy and attenuates high-fat-induced endothelial dysfunction. Front Cell Dev Biol. 2020;8:796.
140. Sun L, Hao Y, An R, Li H, Xi C, Shen G. Overexpression of Rcan1-1L inhibits hypoxia-induced cell apoptosis through induction of mitophagy. Mol Cells. 2014;37:785-94.
141. Pedro JM, Kroemer G, Galluzzi L. Autophagy and mitophagy in cardiovascular disease. Circ Res. 2017;120:1812-24.
142. García-Quintans N, Sánchez-Ramos C, Prieto I, et al. Oxidative stress induces loss of pericyte coverage and vascular instability in PGC-1α-deficient mice. Angiogenesis. 2016;19:217-28.
